<DOC>
	<DOCNO>NCT02650128</DOCNO>
	<brief_summary>Prospective , multi-center , single arm study design evaluate safety performance Shockwave Coronary Rx Lithoplasty® System treat calcify lesion coronary artery purpose enhance placement stent reduce ultimate residual stenosis . Patients follow discharge 30 180 day .</brief_summary>
	<brief_title>Shockwave Coronary Rx Lithoplasty® Study ( Disrupt CAD I )</brief_title>
	<detailed_description>Prospective , multi-center , single arm study design evaluate safety performance Shockwave Coronary Rx Lithoplasty® System treat calcify lesion coronary artery purpose enhance placement stent reduce ultimate residual stenosis . Patients enrol consent study base history instance angiogram obtain prior study . The study design demonstrate Shockwave device safely effectively deliver localized shockwave energy balloon dilatation calcify , stenotic , coronary artery . Subjects prepared PCI per institution 's standard protocol . Medications administer per treatment protocol . Femoral access obtain use 6F access sheath , guide catheter place ostia right leave coronary artery . Baseline angiography culprit lesion perform prior placement 0.014 '' guide wire . Baseline either IVUS OCT perform determine Maximum Lumen Area ( MLA ) , percent stenosis , volumetric lesion assessment . Baseline angiography perform determine lesion length , % stenosis reference vessel diameter . The investigational device prepped per IFU position target lesion . The distal end balloon catheter connect patient cable . The balloon catheter inflate 4 atm investigator deliver 10 pulse 20 second . The balloon inflate reference vessel diameter deflate reestablish flow complete one treatment cycle . The treatment cycle repeat . Angiography either IVUS OCT repeat treat lesion.. A coronary stent deploy site treatment . Angiography either IVUS OCT perform follow stent placement . Patients follow discharge 30 180 day . A subset five ( 5 ) subject receive angiographic assessment 180 day follow visit , per Sponsor 's discretion .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . Patient ≥ 18 year age 2 . Troponin must less equal upper limit lab normal value within 12 hour prior procedure 3 . The target vessel must TIMI flow 3 baseline 4 . Patients significant ( ≥ 50 % diameter stenosis ) native coronary artery disease include stable unstable angina silent ischemia , suitable PCI 5 . Ability tolerate dual antiplatelet agent ( i.e . aspirin , clopidogrel , prasugrel , ticagrelor 1 year single antiplatelet therapy life 6 . Single lesion stenosis protect LMCA , LAD , RCA LCX artery ≥50 % reference vessel 2.5 mm 4.0 mm diameter ≤ 32 mm length 7 . Presence calcification within lesion side vessel assess angiography 8 . Planned treatment single lesion one vessel 9 . Ability pass 0.014 '' guide wire across lesion 10 . Patient , authorized representative , sign write Informed Consent form participate study , prior studymandated procedure 11 . Patient able willing comply assessment study 1 . Concomitant use Atherectomy , Specialty balloon , investigational coronary device 2 . Prior PCI procedure within last 30 day index procedure 3 . Patient plan cardiovascular intervention within 30 day post index procedure 4 . Second lesion ≥50 % stenosis target vessel 5 . Left ventricular ejection fraction &lt; 40 % 6 . Patient refuse candidate emergency coronary artery bypass grafting ( CABG ) surgery 7 . Uncontrolled severe hypertension ( systolic BP &gt; 180 mm Hg diastolic BP &gt; 110 mm Hg ) 8 . Severe renal failure serum creatinine &gt; 2.5 mg/dL 9 . Untreated preprocedural hemoglobin &lt; 10 g/dL 10 . Coagulopathy manifest platelet count &lt; 100,000 International Normalized ratio ( INR ) &gt; 1.7 ( INR require patient take warfarin within 2 week enrollment ) 11 . Patients cardiogenic shock 12 . Acute myocardial infarction ( MI ) within past one ( 1 ) month , and/or elevate TroponinI T ( concomitant elevation CPK ) time enrollment . 13 . History stroke transient ischemic attack ( TIA ) within 3 month 14 . NYHA class III IV heart failure 15 . Active peptic ulcer upper gastrointestinal ( GI ) bleed within 6 month 16 . Patients life expectancy le 1 year 17 . Target vessel &lt; 2.4 mm diameter 18 . Target lesion &gt; 32 mm length 19 . Chronic Total Occlusion ( CTO ) 20 . Previous stent procedure within 5 mm target lesion 21 . Angiographic evidence target lesion severe dissection prior Coronary Lithoplasty treatment 22 . Unprotected Left Main diameter stenosis ≥ 50 % 23 . Visible thrombus ( angiography ) target lesion site 24 . Target lesion locate native vessel distal anastomosis saphenous vein graft LIMA/RIMA bypass 25 . Patient active systemic infection 26 . Patient connective tissue disease ( e.g. , Marfan 's syndrome ) 27 . Patient hypercoagulable disorder 28 . Uncontrolled insulin dependent diabetes 29 . Patient allergy image contrast medium premedicated 30 . Evidence aneurysm target vessel 31 . Patient pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Calcified Coronary Lesions</keyword>
	<keyword>Coronary Arterial Stenosis</keyword>
</DOC>